Class I HDAC inhibition with MS275 (entinostat), which is currently used in clinical trials for cancer (35), resulted in polyuria, kidney NO deficiency, and marked increase in mean arterial pressure within 7 days of salt loading. The gene discussed is HDAC9; the disease is cancer.